JPH07505607A - ステロイドあるいはステロイド様ホルモン応答性病態に対する治療用選択性リガンドの使用 - Google Patents
ステロイドあるいはステロイド様ホルモン応答性病態に対する治療用選択性リガンドの使用Info
- Publication number
- JPH07505607A JPH07505607A JP5504607A JP50460793A JPH07505607A JP H07505607 A JPH07505607 A JP H07505607A JP 5504607 A JP5504607 A JP 5504607A JP 50460793 A JP50460793 A JP 50460793A JP H07505607 A JPH07505607 A JP H07505607A
- Authority
- JP
- Japan
- Prior art keywords
- steroid
- ligand
- rar
- selective
- hormone
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 239000003446 ligand Substances 0.000 title claims abstract description 72
- 239000005556 hormone Substances 0.000 title claims abstract description 39
- 229940088597 hormone Drugs 0.000 title claims abstract description 39
- 230000003637 steroidlike Effects 0.000 title claims abstract description 31
- 230000001225 therapeutic effect Effects 0.000 title description 3
- 238000000034 method Methods 0.000 claims abstract description 49
- 150000003431 steroids Chemical class 0.000 claims abstract description 30
- 238000011282 treatment Methods 0.000 claims abstract description 22
- 102000005962 receptors Human genes 0.000 claims description 36
- 108020003175 receptors Proteins 0.000 claims description 36
- 150000001875 compounds Chemical class 0.000 claims description 34
- 102100023606 Retinoic acid receptor alpha Human genes 0.000 claims description 28
- 108091008726 retinoic acid receptors α Proteins 0.000 claims description 28
- 108091008760 retinoic acid receptors γ Proteins 0.000 claims description 28
- 102100033912 Retinoic acid receptor gamma Human genes 0.000 claims description 27
- 102100033909 Retinoic acid receptor beta Human genes 0.000 claims description 25
- 108091008761 retinoic acid receptors β Proteins 0.000 claims description 25
- 208000024891 symptom Diseases 0.000 claims description 22
- 101001093899 Homo sapiens Retinoic acid receptor RXR-alpha Proteins 0.000 claims description 21
- 102100035178 Retinoic acid receptor RXR-alpha Human genes 0.000 claims description 21
- 108090000623 proteins and genes Proteins 0.000 claims description 19
- 102000003702 retinoic acid receptors Human genes 0.000 claims description 15
- 108090000064 retinoic acid receptors Proteins 0.000 claims description 15
- SHGAZHPCJJPHSC-YCNIQYBTSA-N all-trans-retinoic acid Chemical compound OC(=O)\C=C(/C)\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C SHGAZHPCJJPHSC-YCNIQYBTSA-N 0.000 claims description 12
- 229930002330 retinoic acid Natural products 0.000 claims description 12
- 229960001727 tretinoin Drugs 0.000 claims description 12
- 108010038912 Retinoid X Receptors Proteins 0.000 claims description 10
- 102000034527 Retinoid X Receptors Human genes 0.000 claims description 10
- 150000004492 retinoid derivatives Chemical class 0.000 claims description 10
- 230000001404 mediated effect Effects 0.000 claims description 9
- -1 phenylnaphthyl Chemical class 0.000 claims description 9
- 230000000694 effects Effects 0.000 claims description 8
- 150000001408 amides Chemical class 0.000 claims description 7
- 230000008569 process Effects 0.000 claims description 7
- 230000005945 translocation Effects 0.000 claims description 6
- 210000001685 thyroid gland Anatomy 0.000 claims description 5
- 208000036762 Acute promyelocytic leukaemia Diseases 0.000 claims description 4
- 150000008366 benzophenones Chemical class 0.000 claims description 4
- 101000640876 Homo sapiens Retinoic acid receptor RXR-beta Proteins 0.000 claims description 3
- 208000033826 Promyelocytic Acute Leukemia Diseases 0.000 claims description 3
- 102100034253 Retinoic acid receptor RXR-beta Human genes 0.000 claims description 3
- 102100031241 Thioredoxin reductase 2, mitochondrial Human genes 0.000 claims description 3
- 108010071769 Thyroid Hormone Receptors beta Proteins 0.000 claims description 3
- 239000000470 constituent Substances 0.000 claims description 3
- 208000017520 skin disease Diseases 0.000 claims description 3
- 108091008763 thyroid hormone receptors α Proteins 0.000 claims description 3
- NLFBCYMMUAKCPC-KQQUZDAGSA-N ethyl (e)-3-[3-amino-2-cyano-1-[(e)-3-ethoxy-3-oxoprop-1-enyl]sulfanyl-3-oxoprop-1-enyl]sulfanylprop-2-enoate Chemical compound CCOC(=O)\C=C\SC(=C(C#N)C(N)=O)S\C=C\C(=O)OCC NLFBCYMMUAKCPC-KQQUZDAGSA-N 0.000 claims 2
- HTSGKJQDMSTCGS-UHFFFAOYSA-N 1,4-bis(4-chlorophenyl)-2-(4-methylphenyl)sulfonylbutane-1,4-dione Chemical compound C1=CC(C)=CC=C1S(=O)(=O)C(C(=O)C=1C=CC(Cl)=CC=1)CC(=O)C1=CC=C(Cl)C=C1 HTSGKJQDMSTCGS-UHFFFAOYSA-N 0.000 claims 1
- 150000001735 carboxylic acids Chemical class 0.000 claims 1
- 102000004169 proteins and genes Human genes 0.000 claims 1
- 201000010099 disease Diseases 0.000 abstract description 10
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract description 10
- 239000000126 substance Substances 0.000 description 19
- 231100000673 dose–response relationship Toxicity 0.000 description 15
- 230000004044 response Effects 0.000 description 13
- 229940079593 drug Drugs 0.000 description 6
- 239000003814 drug Substances 0.000 description 6
- 102000027478 retinoid receptor subtypes Human genes 0.000 description 6
- 108091008678 retinoid receptor subtypes Proteins 0.000 description 6
- 150000001732 carboxylic acid derivatives Chemical class 0.000 description 5
- 230000001575 pathological effect Effects 0.000 description 5
- 230000002159 abnormal effect Effects 0.000 description 4
- 230000037361 pathway Effects 0.000 description 4
- 238000012360 testing method Methods 0.000 description 4
- 230000004913 activation Effects 0.000 description 3
- 230000002596 correlated effect Effects 0.000 description 3
- 230000003054 hormonal effect Effects 0.000 description 3
- 101000640882 Homo sapiens Retinoic acid receptor RXR-gamma Proteins 0.000 description 2
- 102100026375 Protein PML Human genes 0.000 description 2
- 102100034262 Retinoic acid receptor RXR-gamma Human genes 0.000 description 2
- 239000002253 acid Substances 0.000 description 2
- 238000002347 injection Methods 0.000 description 2
- 239000007924 injection Substances 0.000 description 2
- 230000004043 responsiveness Effects 0.000 description 2
- 239000003270 steroid hormone Substances 0.000 description 2
- 231100001274 therapeutic index Toxicity 0.000 description 2
- 238000011200 topical administration Methods 0.000 description 2
- 230000001988 toxicity Effects 0.000 description 2
- 231100000419 toxicity Toxicity 0.000 description 2
- 208000002874 Acne Vulgaris Diseases 0.000 description 1
- 208000034951 Genetic Translocation Diseases 0.000 description 1
- 101150016155 Pml gene Proteins 0.000 description 1
- 201000004681 Psoriasis Diseases 0.000 description 1
- 229930003316 Vitamin D Natural products 0.000 description 1
- QYSXJUFSXHHAJI-XFEUOLMDSA-N Vitamin D3 Natural products C1(/[C@@H]2CC[C@@H]([C@]2(CCC1)C)[C@H](C)CCCC(C)C)=C/C=C1\C[C@@H](O)CCC1=C QYSXJUFSXHHAJI-XFEUOLMDSA-N 0.000 description 1
- 206010000496 acne Diseases 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 239000013543 active substance Substances 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- RWCCWEUUXYIKHB-UHFFFAOYSA-N benzophenone Chemical class C=1C=CC=CC=1C(=O)C1=CC=CC=C1 RWCCWEUUXYIKHB-UHFFFAOYSA-N 0.000 description 1
- 239000012965 benzophenone Substances 0.000 description 1
- 102000012740 beta Adrenergic Receptors Human genes 0.000 description 1
- 108010079452 beta Adrenergic Receptors Proteins 0.000 description 1
- 230000037396 body weight Effects 0.000 description 1
- 208000002458 carcinoid tumor Diseases 0.000 description 1
- 239000000969 carrier Substances 0.000 description 1
- 210000004027 cell Anatomy 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 210000000349 chromosome Anatomy 0.000 description 1
- 239000007891 compressed tablet Substances 0.000 description 1
- 239000002552 dosage form Substances 0.000 description 1
- 230000001747 exhibiting effect Effects 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 230000002349 favourable effect Effects 0.000 description 1
- 239000007903 gelatin capsule Substances 0.000 description 1
- 108091008039 hormone receptors Proteins 0.000 description 1
- 238000001794 hormone therapy Methods 0.000 description 1
- 238000002513 implantation Methods 0.000 description 1
- 238000001802 infusion Methods 0.000 description 1
- 230000003993 interaction Effects 0.000 description 1
- 238000007918 intramuscular administration Methods 0.000 description 1
- 238000007912 intraperitoneal administration Methods 0.000 description 1
- 238000001990 intravenous administration Methods 0.000 description 1
- 238000012423 maintenance Methods 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 239000000203 mixture Substances 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 238000012544 monitoring process Methods 0.000 description 1
- AICOOMRHRUFYCM-ZRRPKQBOSA-N oxazine, 1 Chemical compound C([C@@H]1[C@H](C(C[C@]2(C)[C@@H]([C@H](C)N(C)C)[C@H](O)C[C@]21C)=O)CC1=CC2)C[C@H]1[C@@]1(C)[C@H]2N=C(C(C)C)OC1 AICOOMRHRUFYCM-ZRRPKQBOSA-N 0.000 description 1
- 230000008832 photodamage Effects 0.000 description 1
- 102000027483 retinoid hormone receptors Human genes 0.000 description 1
- 108091008679 retinoid hormone receptors Proteins 0.000 description 1
- 238000010254 subcutaneous injection Methods 0.000 description 1
- 239000007929 subcutaneous injection Substances 0.000 description 1
- 238000013268 sustained release Methods 0.000 description 1
- 239000012730 sustained-release form Substances 0.000 description 1
- 229940126585 therapeutic drug Drugs 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 239000005495 thyroid hormone Substances 0.000 description 1
- 229940036555 thyroid hormone Drugs 0.000 description 1
- 108090000721 thyroid hormone receptors Proteins 0.000 description 1
- 102000004217 thyroid hormone receptors Human genes 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- 230000000699 topical effect Effects 0.000 description 1
- 238000001890 transfection Methods 0.000 description 1
- 238000013519 translation Methods 0.000 description 1
- 235000019166 vitamin D Nutrition 0.000 description 1
- 239000011710 vitamin D Substances 0.000 description 1
- 150000003710 vitamin D derivatives Chemical class 0.000 description 1
- 208000030402 vitamin D-dependent rickets Diseases 0.000 description 1
- 229940046008 vitamin d Drugs 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/045—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates
- A61K31/07—Retinol compounds, e.g. vitamin A
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/192—Carboxylic acids, e.g. valproic acid having aromatic groups, e.g. sulindac, 2-aryl-propionic acids, ethacrynic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
- A61K31/196—Carboxylic acids, e.g. valproic acid having an amino group the amino group being directly attached to a ring, e.g. anthranilic acid, mefenamic acid, diclofenac, chlorambucil
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/20—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/20—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids
- A61K31/203—Retinoic acids ; Salts thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
Landscapes
- Health & Medical Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- General Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Diabetes (AREA)
- Oncology (AREA)
- Endocrinology (AREA)
- Dermatology (AREA)
- Hematology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Steroid Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
Description
Claims (15)
- 1.ステロイドあるいはステロイド様ホルモン応答性症状を伴う患者の治療法で あって、当該患者に当該ステロイドあるいはステロイド様ホルモン応答性症状に 関連する受容体亜型と同一受容体群の他のどの亜型よりも有意に高い度合で選択 的に相互反応するリガンドの有効量を投与することを特徴とする当該治療法。
- 2.当該症状がレチノイド応答性であることを特徴とする請求項1の方法。
- 3.当該リガンドがレチノイドX仲介過程に比較し、レチノイン酸仲介過程に対 し、より選択性が高いことを特徴とする請求項2の方法。
- 4.当該リガンドがレチノイン酸仲介過程に比較し、レチノイドX仲介過程に対 し、より選択性が高いことを特徴とする請求項2の方法。
- 5.当該ステロイドあるいはステロイド様応答性症状が受容体のステロイド/甲 状腺上科の一構成分子をコードする遺伝子の一部及び二次遺伝子の一部の転座の 結果によるものであることを特徴とし、その当該二次遺伝子の配列が、受容体ス テロイド/甲状腺の当該構成分子と結合するステロイドあるいはステロイド様ホ ルモンによる調節の際、通常と異なることを特徴とする請求項1の方法。
- 6.当該ステロイドあるいはステロイド様ホルモン応答性症状がAPLであるこ とを特徴とする請求項5の方法。
- 7.当該ステロイドあるいはステロイド様ホルモン応答性症状が皮膚障害である ことを特徴とする請求項1の方法。
- 8.当該ステロイドあるいはステロイド様ホルモン応答性症状に関連する受容体 亜型と選択的に相互反応する当該リガンドが、RAR−α選択性リガンド、RA R−β選択性リガンド、RAR−γ選択性リガンド、TR−α選択性リガンド、 TR−β選択性リガンド、RXR−α選択性リガンド、RXR−β選択性リガン ド、coup−α選択性リガンド、coup−β選択性リガンドまたはcoup −γ選択性リガンドから選択されることを特徴とする請求項1の方法。
- 9.当該RAR−α選択性リガンドが化合物IIIのアミドであることを特徴と する請求項8の方法。
- 10.当該RAR−β選択性リガンドが化合物Iのフエニルーナフチル誘導体あ るいは化合物IVのべンゾフェノン誘導体であることを特徴とする請求項8の方 法。
- 11.当該RAR−γ選択性リガンドが化合物Iのフエニルーナフチル誘導体あ るいは化合物IVのべンゾフェノン誘導体であることを特徴とする請求項8の方 法。
- 12.当該患者にレチノイドX受容体に優先してレチノイン酸受容体と選択的に 相互反応するリガンドの有効量を投与することを特徴とする急性前骨髄球性白血 病患者の治療法。
- 13.当該リガンドがレチノイドX受容体を含めてレチノイン酸受容体の他の亜 型に比較し、より選択的にRAR−αと相互反応することを特徴とする請求項1 2の方法。
- 14.レチノイドX受容体に比較し、レチノイン酸受容体とより選択的に相互反 応する当該リガンドが、化合物IIの多価不飽和カルボン酸であることを特徴と する請求項12の方法。
- 15.RAR−αと選択的に相互反応する当該リガンドが化合物IIIのアミド であることを特徴とする請求項13の方法。
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US74876791A | 1991-08-23 | 1991-08-23 | |
US748,767 | 1991-08-23 | ||
PCT/US1992/007064 WO1993003713A1 (en) | 1991-08-23 | 1992-08-21 | Use of selective ligands for treatment of disease states responsive to steroid or steroid-like hormones |
Publications (1)
Publication Number | Publication Date |
---|---|
JPH07505607A true JPH07505607A (ja) | 1995-06-22 |
Family
ID=25010830
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP5504607A Pending JPH07505607A (ja) | 1991-08-23 | 1992-08-21 | ステロイドあるいはステロイド様ホルモン応答性病態に対する治療用選択性リガンドの使用 |
Country Status (8)
Country | Link |
---|---|
US (1) | US6096787A (ja) |
EP (2) | EP1120113A3 (ja) |
JP (1) | JPH07505607A (ja) |
AT (1) | ATE208194T1 (ja) |
AU (1) | AU2516092A (ja) |
CA (1) | CA2114936C (ja) |
DE (1) | DE69232188T2 (ja) |
WO (1) | WO1993003713A1 (ja) |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2010032582A1 (ja) * | 2008-09-22 | 2010-03-25 | 国立大学法人鹿児島大学 | 成人t細胞白血病治療薬 |
Families Citing this family (22)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
FR2722985B1 (fr) * | 1994-07-27 | 1996-09-13 | Cird Galderma | Nouvelles compositions a base d'un melange synergetique entre au moins un ligand specifique des rxrs et au moins un ligand specifique de rar-x ou de vdr, et leurs utilisations |
FR2723315B1 (fr) * | 1994-08-02 | 1996-10-25 | Cird Galderma | Procede et composition pour stimuler la differenciation des cellules preadipocytaires et traitements therapeutiques associes |
US5807900A (en) * | 1995-03-31 | 1998-09-15 | Hoffmann-La Roche, Inc. | Method for identifying compounds having increased activity for the repair of skin photodamage |
US5624957A (en) * | 1995-06-06 | 1997-04-29 | Bristol-Myers Squibb Company | Rary-specific retinobenzoic acid derivatives |
EP1336600A3 (en) | 1995-10-06 | 2004-07-07 | Ligand Pharmaceuticals Incorporated | Dimer-selective RXR modulators and methods for their use |
US5965606A (en) | 1995-12-29 | 1999-10-12 | Allergan Sales, Inc. | Methods of treatment with compounds having RAR.sub.α receptor specific or selective activity |
US5919970A (en) * | 1997-04-24 | 1999-07-06 | Allergan Sales, Inc. | Substituted diaryl or diheteroaryl methanes, ethers and amines having retinoid agonist, antagonist or inverse agonist type biological activity |
FR2802808B1 (fr) * | 1999-12-22 | 2002-08-09 | Oreal | Utilisation de composes polycycliques aromatiques en tant qu'activateurs des recepteurs de type ppars dans une composition cosmetique ou pharmaceutique |
US20040033600A1 (en) * | 2001-03-21 | 2004-02-19 | Palli Subba Reddy | Ecdysone receptor-based inducible gene expression system |
US8105825B2 (en) * | 2000-10-03 | 2012-01-31 | Intrexon Corporation | Multiple inducible gene regulation system |
EP1373470B1 (en) | 2001-02-20 | 2013-04-24 | Intrexon Corporation | Novel substitution mutant receptors and their use in a nuclear receptor-based inducible gene expression system |
US7531326B2 (en) | 2001-02-20 | 2009-05-12 | Intrexon Corporation | Chimeric retinoid X receptors and their use in a novel ecdysone receptor-based inducible gene expression system |
AU2002248500B2 (en) | 2001-02-20 | 2007-12-13 | Intrexon Corporation | Novel substitution mutant receptors and their use in a nuclear receptor-based inducible gene expression system |
DK1456346T3 (da) | 2001-02-20 | 2012-05-29 | Intrexon Corp | Nyt inducerbart genekspressionssystem baseret på ecdysonreceptor/invertebrat-retinoid-x-receptor |
US7177763B2 (en) * | 2001-09-25 | 2007-02-13 | Werner Keber | Method and device for preventing unpermitted approach of airplanes to objects on the ground which are to be protected |
US7563879B2 (en) * | 2001-09-26 | 2009-07-21 | Intrexon Corporation | Leafhopper ecdysone receptor nucleic acids, polypeptides, and uses thereof |
CA2820170C (en) * | 2001-09-26 | 2016-07-05 | Intrexon Corporation | Whitefly ecdysone receptor nucleic acids, polypeptides, and uses thereof |
US7304161B2 (en) * | 2003-02-10 | 2007-12-04 | Intrexon Corporation | Diaclhydrazine ligands for modulating the expression of exogenous genes in mammalian systems via an ecdysone receptor complex |
US7456315B2 (en) | 2003-02-28 | 2008-11-25 | Intrexon Corporation | Bioavailable diacylhydrazine ligands for modulating the expression of exogenous genes via an ecdysone receptor complex |
US7935510B2 (en) * | 2004-04-30 | 2011-05-03 | Intrexon Corporation | Mutant receptors and their use in a nuclear receptor-based inducible gene expression system |
MX361717B (es) | 2013-03-15 | 2018-12-14 | Intrexon Corp | Diacilhidrazinas que contienen boro. |
WO2016044390A1 (en) | 2014-09-17 | 2016-03-24 | Intrexon Corporation | Boron-containing diacylhydrazine compounds |
Family Cites Families (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP0170105B1 (en) * | 1984-07-07 | 1990-10-17 | Koichi Prof. Dr. Shudo | Benzoic acid derivatives |
IL80270A0 (en) * | 1985-10-11 | 1987-01-30 | Cird | Naphthalene derivatives,their preparation and pharmaceutical compositions containing them |
US4981784A (en) * | 1987-12-02 | 1991-01-01 | The Salk Institute For Biological Studies | Retinoic acid receptor method |
-
1992
- 1992-08-21 AT AT92919124T patent/ATE208194T1/de active
- 1992-08-21 EP EP01103552A patent/EP1120113A3/en not_active Ceased
- 1992-08-21 WO PCT/US1992/007064 patent/WO1993003713A1/en active IP Right Grant
- 1992-08-21 CA CA002114936A patent/CA2114936C/en not_active Expired - Fee Related
- 1992-08-21 JP JP5504607A patent/JPH07505607A/ja active Pending
- 1992-08-21 DE DE69232188T patent/DE69232188T2/de not_active Expired - Fee Related
- 1992-08-21 AU AU25160/92A patent/AU2516092A/en not_active Abandoned
- 1992-08-21 EP EP92919124A patent/EP0600028B1/en not_active Expired - Lifetime
-
1997
- 1997-09-16 US US08/931,694 patent/US6096787A/en not_active Expired - Fee Related
Cited By (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2010032582A1 (ja) * | 2008-09-22 | 2010-03-25 | 国立大学法人鹿児島大学 | 成人t細胞白血病治療薬 |
JP5516894B2 (ja) * | 2008-09-22 | 2014-06-11 | 国立大学法人 鹿児島大学 | 成人t細胞白血病治療薬 |
US8765719B2 (en) | 2008-09-22 | 2014-07-01 | Kagoshima University | Therapeutic drug for adult T-cell leukemia |
Also Published As
Publication number | Publication date |
---|---|
ATE208194T1 (de) | 2001-11-15 |
DE69232188T2 (de) | 2002-06-20 |
EP0600028A1 (en) | 1994-06-08 |
EP1120113A3 (en) | 2003-05-07 |
WO1993003713A1 (en) | 1993-03-04 |
EP0600028B1 (en) | 2001-11-07 |
CA2114936A1 (en) | 1993-03-04 |
CA2114936C (en) | 2004-02-10 |
AU2516092A (en) | 1993-03-16 |
US6096787A (en) | 2000-08-01 |
EP1120113A2 (en) | 2001-08-01 |
DE69232188D1 (de) | 2001-12-13 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JPH07505607A (ja) | ステロイドあるいはステロイド様ホルモン応答性病態に対する治療用選択性リガンドの使用 | |
US5668175A (en) | Use of selective ligands for treatment of disease states responsive to steroid or steroid-like retinoids | |
Carelli | Nucleus accumbens cell firing during goal-directed behaviors for cocaine vs.‘natural’reinforcement | |
Vlachou et al. | GABAB receptors in reward processes | |
DE602004003172T2 (de) | Verfahren zur behandlung von erkrankungen der unteren harnwege mit antimuskarinika und mit modulatoren der alpha-2-delta untereinheit des kalziumkanals | |
Platt | The role of glutamate in central nervous system health and disease–a review | |
Wei et al. | Lithium suppresses excitotoxicity-induced striatal lesions in a rat model of Huntington’s disease | |
UA70315C2 (en) | Pharmaceutical composition comprising metformin anpharmaceutical composition comprising metformin and fibrate useful for formulations intended for lowd fibrate useful for formulations intended for lowering hyperglycemia ering hyperglycemia | |
US20090203792A1 (en) | Methods of treating non-painful bladder disorders using alpha2delta subunit calcium channel modulators | |
KR20070098954A (ko) | 심혈관 사고 예방용 필수 지방산을 포함하는 약제학적조성물 | |
UA65542C2 (uk) | Спосіб пригнічення надлишкового продукування фактора некрозу пухлин альфа , спосіб полегшення шкідливих ефектів надлишкового продукування фактора некрозу пухлин альфа та спосіб лікування запального стану або захворювання, пов'язаного з фактором некрозу пухлин. | |
Tunnicliff | Actions of sodium valproate on the central nervous system | |
Nicholson et al. | Evaluation of the reinforcing properties and phencyclidine-like discriminative stimulus effects of dextromethorphan and dextrorphan in rats and rhesus monkeys | |
Pinel et al. | Controlled demonstration of metrazol kindling | |
JPH0672868A (ja) | 抗精神病薬 | |
Barat et al. | Cocaine and lidocaine in combination are synergistic convulsants | |
DE3940410A1 (de) | Neue verwendung von nmda-rezeptor-antagonisten | |
Marques et al. | Muscle regeneration in dystrophic mdx mice is enhanced by isosorbide dinitrate | |
Code et al. | Preoperative naproxen sodium reduces postoperative pain following arthroscopic knee surgery | |
Tiwari et al. | A review on mechanistic and pharmacological findings of diabetic peripheral neuropathy including pharmacotherapy | |
Fouts | 463 Physiological impairment of drug metabolism | |
Desai et al. | Systemic retinoid therapy: a status report on optimal use and safety of long-term therapy | |
Cosgrove et al. | Differential effects of bremazocine on oral phencyclidine (PCP) self-administration in male and female rhesus monkeys. | |
CA2490308A1 (en) | Use of amino acids for treatment of various conditions | |
CZ112496A3 (en) | Application of ibuprofen and flurbiprofen as agents relieving itching and pharmaceutical preparations for such application |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A02 | Decision of refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A02 Effective date: 20040608 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20041006 Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20041006 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20041118 |
|
A911 | Transfer to examiner for re-examination before appeal (zenchi) |
Free format text: JAPANESE INTERMEDIATE CODE: A911 Effective date: 20041209 |
|
A912 | Re-examination (zenchi) completed and case transferred to appeal board |
Free format text: JAPANESE INTERMEDIATE CODE: A912 Effective date: 20060803 |